A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.

摘要: Meningiomas display significant variability in terms of recurrence and survival rates, even within tumor grade. Although several recent modifications the grading system have improved our ability to predict biologic behavior, additional prognostic markers are needed. Inactivation cell cycle regulator, p16 (CDKN2A), has recently been observed a small subset atypical majority anaplastic meningiomas. To assess potential clinical utility this marker, we performed dual-color FISH on 117 well-characterized archival meningiomas using paired commercial probes chromosome 9 centromeric (CEP9) (9p21) regions. Benign (N = 42) were divided into non-recurring versus recurring groups. Atypical 52) consisted proliferative brain invasive subsets. The 23 not further stratified. Deletion or monosomy was seen 17% benign, 52% atypical, 74% (p < 0.001). No statistically differences found among subsets benign meningioma, though there more recurrences those with deletion. Despite effects regulation, deletions restricted high index. Most importantly, deletion strongly associated meningioma cohort, risk ratio for death 6.79 0.016). Conversely, absence identified patients (26%) prolonged survival. We conclude that 9p21 malignant progression poor prognosis